Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve patient survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results